Quotient Ltd (NASDAQ:QTNT) – Stock analysts at Jefferies Financial Group dropped their Q3 2020 EPS estimates for Quotient in a note issued to investors on Monday, August 5th. Jefferies Financial Group analyst B. Couillard now forecasts that the company will post earnings per share of ($0.39) for the quarter, down from their previous estimate of ($0.38). Jefferies Financial Group also issued estimates for Quotient’s Q4 2020 earnings at ($0.38) EPS, FY2020 earnings at ($1.52) EPS, Q1 2021 earnings at ($0.16) EPS, Q2 2021 earnings at ($0.16) EPS, Q3 2021 earnings at ($0.18) EPS, Q4 2021 earnings at ($0.21) EPS and FY2021 earnings at ($0.71) EPS.
Several other equities analysts have also issued reports on QTNT. ValuEngine lowered shares of Quotient from a “buy” rating to a “hold” rating in a report on Thursday, August 1st. Zacks Investment Research upgraded shares of Quotient from a “sell” rating to a “hold” rating in a report on Wednesday, May 8th. Finally, BidaskClub lowered shares of Quotient from a “buy” rating to a “hold” rating in a report on Thursday.
Quotient (NASDAQ:QTNT) last posted its quarterly earnings data on Monday, August 5th. The company reported ($0.36) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.39) by $0.03. The business had revenue of $8.17 million for the quarter, compared to analysts’ expectations of $8.40 million. Quotient had a negative return on equity of 2,676.12% and a negative net margin of 352.75%.
Several hedge funds have recently added to or reduced their stakes in QTNT. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in Quotient in the 2nd quarter worth approximately $69,000. Niemann Capital Management Inc. purchased a new position in Quotient in the 1st quarter worth approximately $101,000. Resources Investment Advisors Inc. purchased a new position in Quotient in the 1st quarter worth approximately $105,000. Rehmann Capital Advisory Group purchased a new position in Quotient in the 1st quarter worth approximately $154,000. Finally, FNY Investment Advisers LLC purchased a new position in Quotient in the 2nd quarter worth approximately $195,000. Hedge funds and other institutional investors own 63.67% of the company’s stock.
In other news, President Jeremy Stackawitz sold 21,495 shares of Quotient stock in a transaction that occurred on Wednesday, May 29th. The shares were sold at an average price of $9.93, for a total transaction of $213,445.35. Following the completion of the transaction, the president now directly owns 131,939 shares in the company, valued at $1,310,154.27. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Frederick Hallsworth bought 3,150 shares of the stock in a transaction dated Thursday, June 13th. The shares were acquired at an average price of $8.70 per share, with a total value of $27,405.00. Following the completion of the acquisition, the director now directly owns 74,398 shares of the company’s stock, valued at approximately $647,262.60. The disclosure for this purchase can be found here. 14.20% of the stock is currently owned by company insiders.
Quotient Company Profile
Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, and commercializes conventional reagent products used for blood grouping in the transfusion diagnostics market worldwide. The company is developing MosaiQ, a proprietary technology platform, which provides tests for blood grouping and serological disease screening.
Recommended Story: What are popular range trading strategies?
Receive News & Ratings for Quotient Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quotient and related companies with MarketBeat.com's FREE daily email newsletter.